Malignant Pleural Effusion: Pipeline Review, H2 2018 - Featuring Advantagene, Amgen, Biogen and Genelux - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Malignant Pleural Effusion - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Malignant Pleural Effusion - Pipeline Review, H2 2018 provides comprehensive information on the therapeutics under development for Malignant Pleural Effusion (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Pleural Effusion (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Effusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 1 respectively.
Malignant Pleural Effusion (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies FeaturedAdvantagene Inc. Amgen Inc. Biogen Inc. Genelux Corp.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gllphs/malignant_pleural?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005529/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Respiratory Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/17/2018 12:00 PM/DISC: 09/17/2018 12:00 PM